Review
Biochemistry & Molecular Biology
Ivan Henriquez, Mack I. I. I. I. I. I. Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gomez, Oscar Abuchaibe, Felipe Counago
Summary: mCRPC is a complex disease with a wide range of molecular tumor behavior and high risk of progression, making early detection and treatment crucial. Treatment options have improved significantly in recent years, but clinicians find it challenging to keep up with the rapidly changing therapeutic landscape.
Article
Pharmacology & Pharmacy
Jean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, Guilhem Roubaud, Philippe Beuzeboc, Remi Largillier, Delphine Borchiellini, Claude Linassier, Nathalie Ebran, Tanguy Pace-Loscos, Marie-Christine Etienne-Grimaldi, Renaud Schiappa, Jocelyn Gal, Gerard Milano
Summary: A study on 137 advanced prostate cancer patients treated with the first-line anti-androgen agent AA found that polymorphisms of CYP17A1, SLCO2B1, and SLCO1B3 genes were associated with AA pharmacodynamics. This suggests that host genome characteristics can help predict AA treatment efficacy and identify patients at risk for toxicity.
Review
Andrology
Koji Hatano, Norio Nonomura
Summary: The introduction of novel therapeutic agents has expanded the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). However, cross-resistance between treatments may occur, and the optimal treatment sequence must be considered.
WORLD JOURNAL OF MENS HEALTH
(2022)
Article
Oncology
Rebeca Lozano, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H. M. Reid, Ylenia Cendon, Diletta Bianchini, Casilda Llacer, Shahneen K. Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garces, Maria I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. Lopez-Casas, Elena Castro, Johann S. de Bono, David Olmos
Summary: CTC enumeration and changes following treatment have shown superiority over PSA response in determining the outcome of mCRPC patients receiving AR signaling inhibitors but not taxanes. Early changes in CTCs were found to be better predictors of overall survival in mCRPC patients treated with docetaxel compared to PSA response endpoints.
Article
Oncology
Russell K. Pachynski, Chihiro Morishima, Russell Szmulewitz, Lauren Harshman, Leonard Appleman, Paul Monk, Rhonda L. Bitting, Omer Kucuk, Frederick Millard, John D. Seigne, Steven P. Fling, Holden T. Maecker, Caroline Duault, Nirasha Ramchurren, Bruce Hess, Leonard D'Amico, Andreanne Lacroix, Judith C. Kaiser, Michel Morre, Anne Gregoire, Martin Cheever, Evan Y. Yu, Lawrence Fong
Summary: Treatment with rhIL-7 in patients with mCRPC after sip-T led to significant expansion of CD4+ and CD8+ T cells, as well as CD56(bright) natural killer cells, along with improved antigen-specific humoral and T cell proliferative responses over time. Additionally, analysis revealed increased expression of activation markers and beneficial cytokines.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Douglas G. McNeel, Jens C. Eickhoff, Ellen Wargowski, Laura E. Johnson, Christos E. Kyriakopoulos, Hamid Emamekhoo, Joshua M. Lang, Mary Jane Brennan, Glenn Liu
Summary: The combination of programmed cell death 1 blockade and MVI-816 is safe and can enhance tumor-specific T cells, resulting in a favorable 6-month disease control rate. The occurrence of immune-related adverse events is significantly associated with prolonged time on treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Endocrinology & Metabolism
Pierre-Gilles Vestris, Gilles Gourtaud, Cedric Senechal, Yvanne Sadreux, Virginie Roux, Pascal Blanchet, Laurent Brureau
Summary: The study aimed to evaluate the overall and progression-free survival of African ancestry men with mCRPC treated with docetaxel, abiraterone, or enzalutamide. The results suggest the potential benefit of hormonotherapy, particularly abiraterone, as first-line treatment for mCRPC patients of African ancestry.
Article
Oncology
Rosa Sciuto, Sandra Rea, Sara Ungania, Antonella Testa, Valentina Dini, Maria Antonella Tabocchini, Clarice Patrono, Antonella Soriani, Valentina Palma, Raffaella Marconi, Lidia Strigari
Summary: This study investigates personalized treatment with Ra-223, finding a correlation between absorbed dose in target tissue and clinical response, as well as observing chromosome damage during Ra-223 therapy.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fadi Khreish, Niklas Kochems, Florian Rosar, Amir Sabet, Martin Ries, Stephan Maus, Matthias Saar, Mark Bartholomae, Samer Ezziddin
Summary: The study retrospectively analyzed the efficacy of Lu-177-PSMA-617 RLT in treating liver metastases of mCRPC patients, showing that it effectively controlled liver metastases and improved PFShep and OS. The study also found that hepatic tumor burden did not appear to have a significant relationship with treatment efficacy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Oncology
Daniel J. George, Ateesha F. Mohamed, Jui-Hua Tsai, Milad Karimi, Ning Ning, Sayeli Jayade, Marc Botteman
Summary: This study investigated the treatment preferences of mCRPC patients in the US and found that improving overall survival is the highest priority for patients. However, they are willing to make tradeoffs to reduce adverse reactions and side effects.
Article
Oncology
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjostrom, Shuang G. Zhao
Summary: In this study, the researchers identified the intrinsic molecular subtypes of metastatic castration-resistant prostate cancer (mCRPC) and assessed their molecular and clinical correlates using a large cohort with gene expression data. The results showed the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, emphasizing the need for transcriptome-wide profiling in future studies to understand the impact of these differences on treatment responses and outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Nicolas Delanoy, Debbie Robbrecht, Mario Eisenberger, Oliver Sartor, Ronald de Wit, Florence Mercier, Christine Geffriaud-Ricouard, Johann de Bono, Stephane Oudard
Summary: Despite the emergence of new therapies in the past decade, metastatic castration-resistant prostate cancer (mCRPC) remains fatal. Recent research emphasizes the importance of the timing of treatment initiation for patient outcomes, particularly in identifying factors to guide decision-making. A retrospective analysis of the PROSELICA trial suggests that pain progression at the start of cabazitaxel treatment in mCRPC patients is associated with a poorer prognosis, highlighting the need for careful monitoring of disease progression even in the absence of rising PSA levels.
Article
Oncology
Vincenza Conteduca, Chiara Casadei, Emanuela Scarpi, Nicole Brighi, Giuseppe Schepisi, Cristian Lolli, Giorgia Gurioli, Ilaria Toma, Giulia Poti, Alberto Farolfi, Ugo De Giorgi
Summary: This study investigates the correlation between PSA response endpoints, plasma DNA analysis and progression free/overall survival in prostate cancer, highlighting the importance of a multimodal approach in predicting outcomes.
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
